ArticleClinical pharmacology and therapeutics2018

Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study.

Ajit Suri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.